BioIntelliSense, Inc

BioIntelliSense, Inc is a biotechnology startup founded in 2018 based in the United States. The company's slogan, "A New Era of Continuous Health Monitoring and Clinical Intelligence", aligns with its mission to revolutionize Remote Patient Monitoring (RPM). BioIntelliSense offers a medical-grade Data-as-a-Service (DaaS) platform that seamlessly captures vital signs, physiological biometrics, and symptomatic events through its FDA-cleared, medical-grade BioButton® wearable device. This innovative technology enables remote monitoring and early detection, providing clinicians with access to high-resolution patient trending and reporting for effective remote care. The company recently secured a significant $45.00M Series B investment on 28 July 2021 from a notable group of investors, including 7Wire Ventures, Chimera Investments, iD Ventures America, Fresenius Medical Care North America, Pendrell Corporation, James J. Murren, and Mary Tolan. BioIntelliSense is poised to redefine remote patient monitoring through its medical-grade and cost-effective data services, offering a promising opportunity for venture capital investment in the rapidly evolving healthcare technology sector. For more information, visit their website at BioIntelliSense.com.